Stocktoria
Zoetis Inc. ZTS
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2013-02-01
Zoetis Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B |
| SG&A expense | $2.4B | $2.3B | $2.2B | $2.0B | $2.0B |
| Interest expense | $222.0M | $225.0M | $239.0M | $221.0M | $224.0M |
| Income tax | $687.0M | $637.0M | $596.0M | $545.0M | $454.0M |
| Net income | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B |
| EPS (diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| Operating cash flow | $2.9B | $3.0B | $2.4B | $1.9B | $2.2B |
| Free cash flow | $2.3B | $2.3B | $1.6B | $1.3B | $1.7B |
| Cash & equivalents | $2.5B | $2.0B | $2.0B | $3.6B | $3.5B |
| Inventory | $2.5B | $2.3B | $2.6B | $2.3B | $1.9B |
| Total assets | $15.5B | $14.2B | $14.3B | $14.9B | $13.9B |
| Total liabilities | $12.1B | $9.5B | $9.3B | $10.5B | $9.4B |
| Shareholders' equity | $3.4B | $4.8B | $5.0B | $4.4B | $4.5B |
Source: SEC EDGAR filings · CIK 0001555280 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.